New strategic agreements were added in 2018 with two major pharmaceutical companies, Fosun and Ipsen. These partnerships, alongside existing partnerships with Takeda and UCB Pharma, give Arix access to deep scientific knowledge, R&D capabilities, market intelligence and commercial due diligence.
Arix has a strategic partnership with Fosun to invest in and create new companies focused on the development of innovative clinical therapies across a broad range of therapeutic areas, with a particular emphasis on the Chinese market, which is the second largest pharmaceutical market in the world after the United States. The relationship with Fosun will provide a unique footprint and network in the region via sharing of potential investment opportunities in China. Arix provides Fosun with access to its portfolio companies and the potential to promote its services as distribution partner in China.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercialises innovative medicines in three key therapeutic areas – Oncology, Neurosciences and Rare Diseases.
Arix has a strategic partnership with Ipsen to develop and commercialise innovative therapies. Ipsen will gain access to Arix's network of professional and scientific advisors, and the chance to invest in opportunities in Arix's new and existing portfolio companies. In return, Ipsen will contribute research, development, and commercial expertise to the partnership. Arix and Ipsen will collaborate to identify opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients.
In May 2018, Arix announced the formation of 'LAB591' together with Fred Hutchinson Cancer Research Center and Evotec. LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development.
Arix, Evotec and Fred Hutch plan to jointly select promising LAB591 research projects from the Fred Hutch labs. After developing a research validation plan, Evotec will conduct research in collaboration with the Fred Hutch faculty which will be seed funded by Arix. Once completed, and subject to the results, Evotec and Arix have a pre-agreed option to form a new company.